BR112023016601A2 - Antagonistas do canal de cálcio tipo t e usos dos mesmos - Google Patents
Antagonistas do canal de cálcio tipo t e usos dos mesmosInfo
- Publication number
- BR112023016601A2 BR112023016601A2 BR112023016601A BR112023016601A BR112023016601A2 BR 112023016601 A2 BR112023016601 A2 BR 112023016601A2 BR 112023016601 A BR112023016601 A BR 112023016601A BR 112023016601 A BR112023016601 A BR 112023016601A BR 112023016601 A2 BR112023016601 A2 BR 112023016601A2
- Authority
- BR
- Brazil
- Prior art keywords
- calcium channel
- type calcium
- channel antagonists
- cell
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156806P | 2021-03-04 | 2021-03-04 | |
| US202163228505P | 2021-08-02 | 2021-08-02 | |
| PCT/US2022/018682 WO2022216386A2 (en) | 2021-03-04 | 2022-03-03 | T-type calcium channel antagonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016601A2 true BR112023016601A2 (pt) | 2023-12-12 |
Family
ID=83545681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016601A BR112023016601A2 (pt) | 2021-03-04 | 2022-03-03 | Antagonistas do canal de cálcio tipo t e usos dos mesmos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240190865A1 (https=) |
| EP (1) | EP4301759A4 (https=) |
| JP (1) | JP2024508903A (https=) |
| KR (1) | KR20230167035A (https=) |
| AU (1) | AU2022255225A1 (https=) |
| BR (1) | BR112023016601A2 (https=) |
| CA (1) | CA3208202A1 (https=) |
| IL (1) | IL305381A (https=) |
| MX (1) | MX2023010175A (https=) |
| WO (1) | WO2022216386A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024081653A2 (en) * | 2022-10-12 | 2024-04-18 | Acurex Biosciences Corporation | Methods of lowering miro2 to treat neurodegenerative diseases |
| EP4611744A1 (en) * | 2022-10-31 | 2025-09-10 | Acurex Biosciences Corporation | Methods of reducing miro1 or phosphorylated alpha-synuclein |
| CN116813444A (zh) * | 2023-06-28 | 2023-09-29 | 福建凯昕药业有限公司 | 一种1-溴-4-(1-(三氟甲基)环丙基)苯的制备方法 |
| WO2025257786A1 (en) * | 2024-06-13 | 2025-12-18 | Iama Therapeutics S.R.L. | Benzoimidazole derivatives as nkcc1 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610701B2 (en) * | 2001-02-09 | 2003-08-26 | Merck & Co., Inc. | Thrombin inhibitors |
| EP2010493B1 (en) * | 2006-04-12 | 2016-01-27 | Merck Sharp & Dohme Corp. | Pyridyl amide t-type calcium channel antagonists |
| AU2008317353B2 (en) * | 2007-10-24 | 2014-08-07 | Merck Sharp & Dohme Llc | Heterocycle phenyl amide T-type calcium channel antagonists |
| JP2011500808A (ja) * | 2007-10-24 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環アミドt型カルシウムチャネルアンタゴニスト |
| EP2493297B1 (en) * | 2009-10-30 | 2016-08-17 | Merck Sharp & Dohme Corp. | Heterocycle amide t-type calcium channel antagonists |
| CN120118971A (zh) * | 2019-09-05 | 2025-06-10 | 小利兰·斯坦福大学托管委员会 | 修饰线粒体功能的方法和化合物 |
-
2022
- 2022-03-03 JP JP2023553432A patent/JP2024508903A/ja active Pending
- 2022-03-03 CA CA3208202A patent/CA3208202A1/en active Pending
- 2022-03-03 AU AU2022255225A patent/AU2022255225A1/en active Pending
- 2022-03-03 MX MX2023010175A patent/MX2023010175A/es unknown
- 2022-03-03 EP EP22785131.8A patent/EP4301759A4/en active Pending
- 2022-03-03 KR KR1020237033323A patent/KR20230167035A/ko active Pending
- 2022-03-03 WO PCT/US2022/018682 patent/WO2022216386A2/en not_active Ceased
- 2022-03-03 US US18/280,096 patent/US20240190865A1/en active Pending
- 2022-03-03 BR BR112023016601A patent/BR112023016601A2/pt unknown
- 2022-03-03 IL IL305381A patent/IL305381A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023010175A (es) | 2023-09-07 |
| WO2022216386A9 (en) | 2022-12-01 |
| CA3208202A1 (en) | 2022-10-13 |
| EP4301759A2 (en) | 2024-01-10 |
| WO2022216386A2 (en) | 2022-10-13 |
| JP2024508903A (ja) | 2024-02-28 |
| WO2022216386A3 (en) | 2023-01-12 |
| IL305381A (en) | 2023-10-01 |
| US20240190865A1 (en) | 2024-06-13 |
| KR20230167035A (ko) | 2023-12-07 |
| AU2022255225A1 (en) | 2023-09-21 |
| EP4301759A4 (en) | 2025-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023016601A2 (pt) | Antagonistas do canal de cálcio tipo t e usos dos mesmos | |
| EP3870579A4 (en) | TYK2 INHIBITORS AND USES THEREOF | |
| CL2020002161A1 (es) | Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano. | |
| EP3886843A4 (en) | TYK2 INHIBITORS AND USES THEREOF | |
| EP3938369A4 (en) | TYK2 INHIBITORS AND USES THEREOF | |
| EP3914357A4 (en) | TYK2 INHIBITORS AND USES THEREOF | |
| CY1121606T1 (el) | Σκευασματα συνδυασμου νεοσαξιτοξινης για παρατεταμενη τοπικη αναισθησια | |
| MX2018003353A (es) | Terapias con celulas cart con una eficacia mejorada. | |
| MX379543B (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| CL2016000106A1 (es) | Sulfonamidas como moduladores de canales de sodio. | |
| MX2013002275A (es) | Composicion y metodo para reparacion y regeneracion muscular. | |
| AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| SG10201804469RA (en) | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods | |
| CL2021001044A1 (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| DK3972643T3 (da) | Komplementsystemantagonister til anvendelse i fremgangsmåder til behandling af paraproteinemiske neuropatier | |
| BR112016001781A2 (pt) | inibidores de rorc2 e métodos de uso dos mesmos | |
| BR112022004576A2 (pt) | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica | |
| EP3870162A4 (en) | SSAO INHIBITORS AND USES THEREOF | |
| JOP20230157A1 (ar) | طرق مُعالجة فيروس كورونا | |
| PL4038503T3 (pl) | Sposób wykrywania ataków przez powtórzenie w systemach gnss i służące do tego urządzenia | |
| EA202190440A1 (ru) | Длительное введение ласмидитана на ночь для профилактики мигрени | |
| JOP20250103A1 (ar) | طرق للعلاج أو الوقاية من ضمور العضلات النخاعي | |
| BR112017024672B8 (pt) | Kit de inserção de um implante endósseo unitário | |
| MX2021000542A (es) | Apirasas solubilizadas, metodos y usos. |